<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071600</url>
  </required_header>
  <id_info>
    <org_study_id>13038</org_study_id>
    <nct_id>NCT04071600</nct_id>
  </id_info>
  <brief_title>Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder</brief_title>
  <official_title>Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder (ASD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westchester Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Level 2 trauma patients admitted to Westchester Medical Center who consent and meet the
      inclusion criteria will answer a questionnaire, be tested on Beck Anxiety Index, assessed for
      vital signs and provide blood and urine samples for biomarker testing. before the
      intervention.

      Part 1 Dose Escalation: Subjects will receive a single infusion NPY or vehicle delivered to
      the upper nasal cavity with an intranasal device. The administration of intranasal NPY will
      follow the 3 plus 3 model and Fibonacci dose escalation scheme.

      Subjects will be assessed for Acute Stress Disorder (ASD) on the National Stressful Events
      Survey Acute Stress Disorder Sheet (NSESSS) at 3-7 and at 14-30 days post trauma, At &gt;60 days
      post trauma to be evaluated with the PTSD Symptom Scale Interview for DSM-5 (PSS-I-5) and
      given the Beck Anxiety Inventory test.

      Part 2 Dose Expansion Cohort: Once the maximal tolerated dose (MTD) is determined, we will
      follow it by a dose expansion cohort to obtain preliminary evidence of efficacy of intranasal
      NPY to alter the severity of ASD and inhibit the progression to PTSD and the usefulness of
      several biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted to the Westchester Medical Center as a level 2 trauma patient who meet the
      admission criteria will be asked to join the study and written consent will be obtained.
      Every patient who consents to participate will fill out a questionnaire of general
      information including education level, marital status, social support etc. and administered
      the Beck Anxiety Inventory. They will be asked to collect urine samples until the next
      morning.

      The next morning at about 9-11 AM vital signs will be measured, including standing systolic
      blood pressure. Blood and the overnight urine samples will be collected for biomarker
      testing. This will include urinary norepinephrine levels, plasma ACTH and epigenetic changes
      in the genes for glucocorticoid receptor and norepinephrine transporter.

      Subjects will then receive intranasal NPY (GMP-grade) delivered to the upper nasal cavity
      with an intranasal device from Kurve. We have chosen this device since it appears to be the
      best delivery system to the upper olfactory region of the nose for delivery to the brain. It
      has been used most widely, including the earlier clinical trial with intranasal NPY. After
      the intranasal NPY, patients will be evaluated for potential adverse reactions and vital
      signs measured at 30 min, 90 min, and every 4 hrs until released from the hospital. 1 and 3
      days after the intranasal infusion.

      The dose escalation of intranasal NPY will follow the 3 plus 3 model and Fibonacci dose
      escalation scheme with a starting dose of 9.6mg, selected based on the highest previously
      studied dose (Sayed et al. 2018). According to this model if no participant has a dose
      limiting toxicity (DLT), we will proceed to the next dose. If 1/3 has a DLT, 3 additional
      participants will be enrolled and if more than 1/6 have a DLT the dose escalation will be
      terminated.

      A DLT will be defined as an adverse event or a clinically significant change in vital signs
      as follows: (1) any serious adverse event experienced at any time during the study that was
      determined to be at least &quot;possibly&quot; related to the study drug, or (2) a non-serious adverse
      event rated at least moderate in severity and at least &quot;possibly&quot; related to the study drug,
      or (3) occurrence of any of the following changes in vital signs with 90 minutes following
      administration of the NPY: (i) symptomatic hypotension or &gt;20% decrease in systolic blood
      pressure (SBP) and an absolute SBP &lt; 90; (ii) symptomatic hypertension or &gt;20% increase in
      SBP and an absolute SBP &gt;170 or diastolic blood pressure (DBP) &gt; 95; (iii) new onset of
      tachyarrhythmia (defined as a heart rate &gt;100 bpm) or symptomatic bradycardia (heart rate &lt;60
      bpm).

      Tests for Persistent ASD and Development of PTSD At 3-7 and 14-30 days post trauma, subjects
      will be asked to fill out the National Stressful Events Survey Acute Stress Disorder Short
      Scale (NSESSS). After at least 60 days from the trauma they will be given an interview to be
      evaluated with the PTSD Symptom Scale Interview for DSM-5 (PSS-I-5) as well as the Beck
      Anxiety Inventory.

      Dose escalation cohort After reaching the maximal tolerated dose (MTD) of intranasal NPY or
      four dose escalation steps without reaching a DLT, we will add a dose escalation cohort. The
      individuals in this cohort will be randomly assigned to be administered intranasal NPY or
      vehicle (placebo).

      Based on the statistical analysis, we hope to be able to expand to 25-33 individuals per
      group in order to detect a 15% reduction in incidence of PTSD beyond the influence of the
      placebo with power of 80%.

      Subjects will be tested for: Persistent ASD (NSESS) at days 3-7 and 14-30 after the trauma,
      PTSD and t 3-7 and 14-30 days post trauma: development of PTSD ( PSS-I-5), &gt; 60 days post
      trauma); and anxiety (Beck Anxiety Inventory) and compared to groups given no intervention.

      The information is expected provide preliminary data on efficacy of intranasal NPY
      administration to reduce the severity of ASD and attenuate the progression to PTSD. In
      addition, the results should provide preliminary information on usefulness of several
      biomarkers to inform on the progression of ASD and PTSD in level 2 trauma patients and on the
      response to intranasal NPY.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6-9 months</time_frame>
    <description>Dose escalation until treatment emergent adverse effect</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary indication of efficacy of intranasal NPY compared to placebo and no intervention for PTSD</measure>
    <time_frame>2-3 years</time_frame>
    <description>Rating for likely PTSD on PSS-I-5 a 20 item interview &gt;60 days after the trauma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary indication of efficacy of intranasal NPY compared to placebo and no intervention for early Acute Stress Disorder (ASD)</measure>
    <time_frame>2-3 years</time_frame>
    <description>Rating on National Stressful Events Survey Acute Stress Disorder Short Form (NSESS) 3-7 days after traum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preliminary indication of efficacy of intranasal NPY compared to placebo and no intervention for prolonged Acute Stress Disorder (ASD)</measure>
    <time_frame>2-3 years</time_frame>
    <description>Rating on National Stressful Events Survey Acute Stress Disorder Short Form (NSESS) 14-30 days after trauma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary indication of efficacy of intranasal NPY compared to placebo and no intervention for anxiety</measure>
    <time_frame>2-3 years</time_frame>
    <description>Scores on Beck Anxiety Inventory (BAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary indication of usefulness of blood pressure to predict development of ASD and PTSD and response to intranasal NPY</measure>
    <time_frame>3 years</time_frame>
    <description>Blood pressure measured sitting and standing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary indication of usefulness of urinary norepinephrine to predict development of ASD and PTSD and usefulness of intranasal NPY</measure>
    <time_frame>3 years</time_frame>
    <description>Urinary norepinephrine levels by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary indication of usefulness of plasma ACTH to predict development of ASD and PTSD and response to intranasal NPY</measure>
    <time_frame>3 years</time_frame>
    <description>Plasma ACTH by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary indication of usefulness of epigentic changes in GR and NET genes to predict development of ASD and PTSD and response to intranasal NPY</measure>
    <time_frame>3 years</time_frame>
    <description>Methylation of the genes for glucocorticoid receptor (GR) and Norepinephrine Transporter (NET)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <condition>Stress Disorders, Traumatic, Acute</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Type two trauma patients randomly assigned to be administered the vehicle (water) with Kurve intranasal device once and followed for up to 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuropeptide Y</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The individuals in this arm will be randomly assigned to be administered intranasal NPY with Kurve intranasal device once and will be followed for at least 60 days afterwards for development of Acute Stress Disorder and Posttraumatic Stress Disorder.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The individuals in this arm will be randomly assigned and treated the same as the other arms but with no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuropeptide Y</intervention_name>
    <description>Intranasal</description>
    <arm_group_label>Neuropeptide Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intranasal</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Level 2 trauma patients admitted to the trauma floors or trauma ICU at Westchester
             Medical Center

          -  Experienced fear at the time of the trauma

        Exclusion Criteria:

          -  Vulnerable populations, such as pregnant women, prisoners, persons with decisional
             incapacity.

          -  History of coronary artery disease, heart failure, prior stroke, heart surgery

          -  Bood pressure &gt;160/90

          -  Acutely psychotic

          -  Current diagnosis of anorexia nervosa, bulimia

          -  Current diagnosis of cancer

          -  Drug abuse or dependence in the preceding 3 months,

          -  Any unstable medical condition

          -  Active suicidal/homicidal ideation

          -  Cannot speak, read, write and understand English at least at 8th grade level.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Sabban, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rhea Dornbush, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yvette Smolin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westchestr Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther L Sabban, PhD</last_name>
    <phone>9145944068</phone>
    <email>sabban@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvette Smolin, MD</last_name>
    <phone>9144931310</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Esther L Sabban, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sayed S, Van Dam NT, Horn SR, Kautz MM, Parides M, Costi S, Collins KA, Iacoviello B, Iosifescu DV, Math√© AA, Southwick SM, Feder A, Charney DS, Murrough JW. A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. Int J Neuropsychopharmacol. 2018 Jan 1;21(1):3-11. doi: 10.1093/ijnp/pyx109.</citation>
    <PMID>29186416</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>August 25, 2019</last_update_submitted>
  <last_update_submitted_qc>August 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Esther Sabban</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>neuropeptide Y</keyword>
  <keyword>intranasal</keyword>
  <keyword>biomarkers</keyword>
  <keyword>anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Traumatic, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

